BWX Technologies, Inc. reported Q2 2023 revenue of $902M, up 18% YoY. Adjusted EBITDA increased 7%, while free cash flow guidance was raised by $30M.
BWX Technologies, Inc. reported Q2 2023 revenue of $902 million, an increase of 18% year-over-year, surpassing the $872 million consensus estimate. The strong performance was driven by both commercial and government operations, highlighting the company's expanding market presence in the nuclear sector amid increasing global demand.
Key Takeaways
- Total revenue rose to $902 million, up 18% YoY, driven by a 72% spike in commercial operations revenue.
- Adjusted EBITDA increased 7% to $156 million, reflecting growth in commercial operations despite lower government segment performance.
- Free cash flow reached $115 million, leading to a revised full-year guidance increase of $30 million to $345 million to $360 million.
- Backlog rose 40% YoY to $8.4 billion, with a book-to-bill ratio of 1.7 indicating strong order demand.
Strong Revenue Growth Driven by Commercial Operations
BWXT's commercial operations revenue surged 72% year-over-year, reflecting robust demand across commercial nuclear power and nuclear medicine segments. Adjusted EBITDA for the commercial segment more than doubled to $36 million, with an EBITDA margin of 11.9%. The increase is attributed to higher activity in Canadian field services and aftermarket support, along with contributions from the Conetrix acquisition. As the nuclear market expands, BWXT anticipates securing at least one new nuclear equipment order by year-end, showcasing the growing momentum in customer discussions.
| Metric | Q2 2023 | YoY | QoQ |
|---|---|---|---|
| Revenue | $902M | +18% | N/A |
| Adjusted EBITDA | $156M | +7% | N/A |
| Free Cash Flow | $115M | N/A | N/A |
| Backlog | $8.4B | +40% | N/A |
Adjusted Guidance Reflects Strong Performance
Management raised its full-year free cash flow guidance to a range of $345 million to $360 million, up from prior estimates. This revision is supported by solid first-half performance and anticipated milestones in the second half. Additionally, the company's adjusted EBITDA guidance for 2026 has also been increased by $10 million to a range of $662 million to $672 million, reflecting strong year-to-date execution and continued operational improvements.
However, the company revised its government operations revenue growth expectation from low teens to high single digits due to stronger cost performance, particularly in the High Purity Depleted Uranium (HPDU) program. Despite this, adjusted EBITDA margin guidance for government operations has been raised to approximately 20.5% from greater than 19%.
Strategic Divestiture of Medical Business
BWXT's recent sale of its medical business for up to $800 million allows the company to sharpen its focus on its core nuclear operations. The divestiture, which represented only 3% of total sales, frees up resources for investment in national nuclear security and commercial nuclear power markets. The company retains a 20% equity stake in the sold assets, ensuring some continued participation in potential growth.
Management emphasized that the proceeds will be allocated to internal investments and strategic acquisitions, aiming to enhance the company’s capabilities in its high-growth sectors. This strategic shift positions BWXT to better capitalize on the expanding nuclear market while maintaining financial flexibility.
Analyst Q&A Highlights
During the Q&A session, analysts probed management on the anticipated impacts of the Navy's 30-year shipbuilding plan, which includes sustained production of Virginia-class submarines and accelerated Ford-class aircraft carrier procurement. Rex Geveden, President and CEO, noted that the new cadence is expected to stabilize production volumes, significantly benefitting BWXT’s revenue consistency in the coming years.
Additionally, management discussed the potential for new nuclear equipment orders, highlighting ongoing discussions with major reactor vendors and expressing optimism about securing contracts by year-end. There was also an emphasis on ongoing challenges in the labor market, particularly in finding qualified tradespeople, which BWXT is actively managing.
Closing Thoughts
BWXT's strong Q2 results and upward revisions to guidance reflect its robust positioning in the nuclear sector. With a healthy backlog and strategic focus following the divestiture of its medical business, the company appears well-prepared to leverage growth opportunities in both government and commercial markets. However, as BWXT continues to expand its operational capabilities, the upcoming quarters will reveal how effectively it can convert its backlog into revenue amidst evolving market dynamics.
This analysis is based on public earnings call materials and is not investment advice.
